Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018

By Todd Campbell - Updated Apr 15, 2019 at 5:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage biotech hopes to tap into what could be a megablockbuster indication.

What happened

After results from clinical trials sparked investors' hope that the company's approach to tackling nonalcoholic steatohepatitis (NASH) will pan out, shares in Viking Therapeutics (VKTX 4.33%) soared 88.4% in 2018, according to S&P Global Market Intelligence.

So what

Shareholders' good fortune began in earnest in May when Madrigal Pharmaceuticals (MDGL -0.50%) reported updated, positive results from a midstage trial evaluating a drug that works similarly to Viking Therapeutics' lead drug candidate, VK2809.

A man in a suit draws a picture of a rocket soaring through space.


Madrigal's data showed that at the 36-week mark, liver fat was reduced by an average of 37%. Also, 39% of patients who had responded to MGL-3196 at 12 weeks achieved NASH resolution at 36 weeks, leading to speculation that up to 40% of patients receiving this type of therapy could see NASH resolution within nine months.

The results prompted rallies in both Madrigal and Viking Therapeutics' shares, because MGL-3196 and VK2809 both boost thyroid hormone activity by selectively targeting thyroid beta receptors to increase metabolism and fat clearance. Investors who took the chance of buying Viking Therapeutics on hopes VK2809 would put up similarly strong results in its trial were rewarded in September, when Viking unveiled its own positive data.

Specifically, 90.9% of patients receiving VK2809 saw a 30% or greater reduction in liver fat at 12 weeks; overall, the average reduction was 59.7%. The data shouldn't be compared to Madrigal's directly, because each company studied its drug in different patients, but nonetheless, it was an encouraging finding; it prompted Viking Therapeutics CEO Brian Lian to say, "VK2809's effect on liver fat at 12 weeks appears to exceed all other oral agents currently in development for NASH."

Now what

NASH is quickly becoming the most common reason for liver transplant. A silent disease, it's often underdiagnosed. But estimates are that there are 3 million cases of nonalcoholic fatty liver disease in the U.S. annually, and roughly 20% of those cases are NASH.

The sheer size of the addressable market has industry analysts projecting that spending on NASH medications could swell, especially as the incidence of fatty liver disease increases due to sedentary lifestyles and high-fat diets. The possibility of this becoming a megablockbuster indication, and the fact that Viking Therapeutics' market cap is only $613 million, suggest that if the company continues to post strong results for VK2809, the run-up in its share price may not be over.

Check out the latest Viking Therapeutics earnings call transcript.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viking Therapeutics, Inc. Stock Quote
Viking Therapeutics, Inc.
$2.89 (4.33%) $0.12
Madrigal Pharmaceuticals, Inc. Stock Quote
Madrigal Pharmaceuticals, Inc.
$71.58 (-0.50%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.